157 related articles for article (PubMed ID: 11697713)
1. Use of a low-molecular-weight heparinoid (danaparoid sodium) for continuous renal replacement therapy in intensive care patients.
Lindhoff-Last E; Betz C; Bauersachs R
Clin Appl Thromb Hemost; 2001 Oct; 7(4):300-4. PubMed ID: 11697713
[TBL] [Abstract][Full Text] [Related]
2. Prospective randomised open-label comparison of danaparoid with dextran 70 in the treatment of heparin-induced thrombocytopaenia with thrombosis: a clinical outcome study.
Chong BH; Gallus AS; Cade JF; Magnani H; Manoharan A; Oldmeadow M; Arthur C; Rickard K; Gallo J; Lloyd J; Seshadri P; Chesterman CN;
Thromb Haemost; 2001 Nov; 86(5):1170-5. PubMed ID: 11816702
[TBL] [Abstract][Full Text] [Related]
3. Danaparoid for heparin-induced thrombocytopenia: an analysis of treatment failures.
Kodityal S; Manhas AH; Udden M; Rice L
Eur J Haematol; 2003 Aug; 71(2):109-13. PubMed ID: 12890149
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and pharmacodynamics of danaparoid during continuous venovenous hemofiltration: a pilot study.
de Pont AC; Hofstra JJ; Pik DR; Meijers JC; Schultz MJ
Crit Care; 2007; 11(5):R102. PubMed ID: 17854496
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of danaparoid sodium (ORG 10172) in critically ill patients with heparin-associated thrombocytopenia.
Tardy-Poncet B; Tardy B; Reynaud J; Mahul P; Mismetti P; Mazet E; Guyotat D
Chest; 1999 Jun; 115(6):1616-20. PubMed ID: 10378558
[TBL] [Abstract][Full Text] [Related]
6. Comparing subcutaneous danaparoid with intravenous unfractionated heparin for the treatment of venous thromboembolism. A randomized controlled trial.
de Valk HW; Banga JD; Wester JW; Brouwer CB; van Hessen MW; Meuwissen OJ; Hart HC; Sixma JJ; Nieuwenhuis HK
Ann Intern Med; 1995 Jul; 123(1):1-9. PubMed ID: 7539233
[TBL] [Abstract][Full Text] [Related]
7. On the prophylactic and therapeutic use of danaparoid sodium (Orgaran) in patients with heparin-induced thrombocytopenia.
Schenk JF; Pindur G; Stephan B; Mörsdorf S; Mertzlufft F; Kroll H; Wenzel E; Seyfert UT
Clin Appl Thromb Hemost; 2003 Jan; 9(1):25-32. PubMed ID: 12643320
[TBL] [Abstract][Full Text] [Related]
8. Cardiopulmonary bypass with danaparoid sodium and ancrod in heparin-induced thrombocytopenia.
Kanagasabay RR; Unsworth-White MJ; Robinson G; Bevan D; Farnsworth G; Haxby EJ; Smith EE
Ann Thorac Surg; 1998 Aug; 66(2):567-9. PubMed ID: 9725413
[TBL] [Abstract][Full Text] [Related]
9. Intraoperative monitoring of danaparoid sodium anticoagulation during cardiovascular operations.
Gitlin SD; Deeb GM; Yann C; Schmaier AH
J Vasc Surg; 1998 Mar; 27(3):568-75. PubMed ID: 9546248
[TBL] [Abstract][Full Text] [Related]
10. A comparison of danaparoid and lepirudin in heparin-induced thrombocytopenia.
Farner B; Eichler P; Kroll H; Greinacher A
Thromb Haemost; 2001 Jun; 85(6):950-7. PubMed ID: 11434701
[TBL] [Abstract][Full Text] [Related]
11. Thromboembolic prophylaxis with danaparoïd (Orgaran) in a high-thrombosis-risk pregnant woman with a history of heparin-induced thrombocytopenia (HIT) and Widal's disease.
Macchi L; Sarfati R; Guicheteau M; Chamlian V; Pourrat O; Gruel Y; Magnin G; Brizard A; Boinot C
Clin Appl Thromb Hemost; 2000 Oct; 6(4):187-9. PubMed ID: 11030522
[TBL] [Abstract][Full Text] [Related]
12. Lifesaving citrate anticoagulation to bridge ineffective danaparoid [correction of to bridge to danaparoid] treatment.
Dworschak M; Hiesmayr JM; Lassnigg A
Ann Thorac Surg; 2002 May; 73(5):1626-7. PubMed ID: 12022563
[TBL] [Abstract][Full Text] [Related]
13. Danaparoid cross-reactivity with heparin-induced thrombocytopenia antibodies: report of 12 cases.
Tardy-Poncet B; Wolf M; Lasne D; Bauters A; Ffrench P; Elalamy I; Tardy B
Intensive Care Med; 2009 Aug; 35(8):1449-53. PubMed ID: 19350215
[TBL] [Abstract][Full Text] [Related]
14. Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke: a randomized controlled trial. The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators.
JAMA; 1998 Apr 22-29; 279(16):1265-72. PubMed ID: 9565006
[TBL] [Abstract][Full Text] [Related]
15. Danaparoid sodium.
Acostamadiedo JM; Iyer UG; Owen J
Expert Opin Pharmacother; 2000 May; 1(4):803-14. PubMed ID: 11249517
[TBL] [Abstract][Full Text] [Related]
16. Use of danaparoid sodium (Orgaran) as an alternative to heparin sodium during cardiopulmonary bypass: a clinical evaluation of six cases.
Fernandes P; Mayer R; MacDonald JL; Cleland AG; Hay-McKay C
Perfusion; 2000 Nov; 15(6):531-9. PubMed ID: 11131218
[TBL] [Abstract][Full Text] [Related]
17. Danaparoid. A review of its pharmacology and clinical use in the management of heparin-induced thrombocytopenia.
Wilde MI; Markham A
Drugs; 1997 Dec; 54(6):903-24. PubMed ID: 9421696
[TBL] [Abstract][Full Text] [Related]
18. Treatment of 51 pregnancies with danaparoid because of heparin intolerance.
Lindhoff-Last E; Kreutzenbeck HJ; Magnani HN
Thromb Haemost; 2005 Jan; 93(1):63-9. PubMed ID: 15630492
[TBL] [Abstract][Full Text] [Related]
19. Heparin-induced thrombocytopenia type II: perioperative management using danaparoid in a coronary artery bypass patient with renal failure.
Westphal K; Martens S; Strouhal U; Matheis G; Lindhoff-Last E; Wimmer-Greinecker G; Lischke V
Thorac Cardiovasc Surg; 1997 Dec; 45(6):318-20. PubMed ID: 9477469
[TBL] [Abstract][Full Text] [Related]
20. [Heparin induced thrombocytopenia and anticoagulation in renal replacemant therapy].
Steinfeldt T; Rolfes C
Anasthesiol Intensivmed Notfallmed Schmerzther; 2008 Apr; 43(4):304-10; quiz 312. PubMed ID: 18409125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]